Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202404 | PMC |
http://dx.doi.org/10.1099/acmi.0.000561.v3 | DOI Listing |
Korean J Anesthesiol
January 2025
Division of Neuroanaesthesiology, International Institute of Neurosciences, Aster Whitefield Hospital, Bengaluru, Karnataka, India.
Neurospine
December 2024
Department of Neurosurgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Eur Respir J
January 2025
Assistance Publique Hôpitaux Paris (AP-HP), Hôpital Bichat, Département de Médecine Interne, Paris, France
Sociol Health Illn
January 2025
Department of Global Health and Social Medicine, King's College London, London, UK.
The National Institute for Health and Care Excellence (NICE) was established a quarter of a century ago in 1999 to regulate the cost-effectiveness of pharmaceuticals (and other health technologies) for the NHS. Drawing on medical sociology theories of corporate bias, neoliberalism, pluralism/polycentricity and regulatory capture, the purpose of this article is to examine the applicability of those theories to NICE as a key regulatory agency in the UK health system. Based on approximately 7 years of documentary research, interviews with expert informants and observations of NICE-related meetings, this paper focuses particularly on NICE's relationship with the interests of the pharmaceutical industry compared with other stakeholder interests at the meso-organisational level.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!